Growth hormone therapy in children: when to stop?

Area of Science:

• Pediatrics
• Endocrinology
• Growth and Development

Background:

• Growth hormone (GH) therapy is used for short stature, but guidelines for initiating and discontinuing treatment are not standardized.
• Current practices often rely on height velocity and remaining growth potential, which may not fully capture treatment efficacy or long-term outcomes.

Purpose of the Study:

• To review the complexities surrounding the decision-making process for stopping GH treatment in children with short stature.
• To highlight the need for a more comprehensive understanding of GH's biological roles beyond linear growth.

Main Methods:

• Literature review and synthesis of current clinical guidelines and research findings on GH therapy.
• Analysis of the potential consequences of discontinuing GH treatment, particularly in cases of GH deficiency.

Main Results:

• There is no universal consensus on the optimal timing for GH treatment cessation.
• Decisions are influenced by disease specifics, individual patient circumstances, and socio-economic factors.
• Stopping GH therapy prematurely can lead to retarded GH-dependent gonadal or bone development, even if normal height is achieved.

Conclusions:

• The decision to discontinue GH treatment should be individualized and informed by evolving knowledge of GH's complex biological functions.
• Adherence to convention should be replaced by a nuanced approach considering the full spectrum of GH's effects.
• Further research is needed to establish evidence-based criteria for optimizing GH treatment duration.